Tourmaline Bio, Inc.
TRMLNASDAQHealthcare
$47.98
+$0.00(+0.00%)
Market Cap$1.2B
P/E Ratio—
52W High$48.27
52W Low$11.56
Tourmaline Bio, Inc. (TRML) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TRML · earnings · updated Jun 8, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 6, 2025EPS Actual
-$0.78
Est. -$0.96 · +18.8%
Revenue
—
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 6, 2025
After Market Close
▲ Beat EPS🔥 7-Quarter EPS Beat Streak
TRML reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.96 | -$0.78 | +18.8% | — | — | — |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$0.94 | -$0.90 | +4.3% | — | — | — |
| ▲ Q2 FY2025 | May 2, 2025 | -$0.91 | -$0.89 | +2.2% | — | — | — |
| ▲ Q1 FY2025 | Mar 13, 2025 | -$0.91 | -$0.86 | +5.5% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.84 | -$0.78 | +7.1% | — | — | — |
| ▲ Q3 FY2024 | Aug 8, 2024 | -$0.72 | -$0.68 | +5.6% | — | — | — |
| ▲ Q2 FY2024 | May 13, 2024 | -$0.68 | -$0.55 | +19.1% | — | — | — |
| ▼ Q1 FY2024 | Mar 19, 2024 | -$0.75 | -$0.81 | -8.0% | $0.00B | — | — |
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.78
EPS Est.
-$0.96
EPS Surpr.
+18.8%
Revenue
—
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.90
EPS Est.
-$0.94
EPS Surpr.
+4.3%
Revenue
—
Q2 FY2025
May 2, 2025Beat
EPS Actual
-$0.89
EPS Est.
-$0.91
EPS Surpr.
+2.2%
Revenue
—
Q1 FY2025
Mar 13, 2025Beat
EPS Actual
-$0.86
EPS Est.
-$0.91
EPS Surpr.
+5.5%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.78
EPS Est.
-$0.84
EPS Surpr.
+7.1%
Revenue
—
Q3 FY2024
Aug 8, 2024Beat
EPS Actual
-$0.68
EPS Est.
-$0.72
EPS Surpr.
+5.6%
Revenue
—
Q2 FY2024
May 13, 2024Beat
EPS Actual
-$0.55
EPS Est.
-$0.68
EPS Surpr.
+19.1%
Revenue
—
Q1 FY2024
Mar 19, 2024Miss
EPS Actual
-$0.81
EPS Est.
-$0.75
EPS Surpr.
-8.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-1.06 | $-1.06 | $-1.06 | 1 |
| Q3 FY2026 | $-1.03 | $-1.03 | $-1.03 | 1 |
| Q2 FY2026 | $-1.02 | $-1.02 | $-1.02 | 1 |
| Q1 FY2026 | $-1.02 | $-1.02 | $-1.02 | 1 |
| Q4 FY2025 | $-1.19 | $-0.98 | $-0.89 | 5 |
| Q3 FY2025 | $-1.06 | $-0.95 | $-0.90 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 4 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2025 | Nov 6, 2025 | +18.8% | $47.98 | — | — |
| ▲ Q3 FY2025 | Aug 13, 2025 | +4.3% | $21.48 | $22.22 | +3.45% |
| ▲ Q2 FY2025 | May 2, 2025 | +2.2% | $17.85 | $16.30 | -8.68% |
| ▲ Q1 FY2025 | Mar 13, 2025 | +5.5% | $16.27 | $17.04 | +4.73% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +7.1% | $27.40 | $27.66 | +0.95% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +5.6% | $13.70 | $14.54 | +6.13% |
| ▲ Q2 FY2024 | May 13, 2024 | +19.1% | $14.50 | $14.44 | -0.41% |
| ▼ Q1 FY2024 | Mar 19, 2024 | -8.0% | $40.01 | $40.33 | +0.80% |
Q4 FY2025—
Report Date
Nov 6, 2025
EPS Beat/Miss
+18.8%
Price Before
$47.98
Price After
—
Q3 FY2025+3.45%
Report Date
Aug 13, 2025
EPS Beat/Miss
+4.3%
Price Before
$21.48
Price After
$22.22
Q2 FY2025-8.68%
Report Date
May 2, 2025
EPS Beat/Miss
+2.2%
Price Before
$17.85
Price After
$16.30
Q1 FY2025+4.73%
Report Date
Mar 13, 2025
EPS Beat/Miss
+5.5%
Price Before
$16.27
Price After
$17.04
Q4 FY2024+0.95%
Report Date
Nov 7, 2024
EPS Beat/Miss
+7.1%
Price Before
$27.40
Price After
$27.66
Q3 FY2024+6.13%
Report Date
Aug 8, 2024
EPS Beat/Miss
+5.6%
Price Before
$13.70
Price After
$14.54
Q2 FY2024-0.41%
Report Date
May 13, 2024
EPS Beat/Miss
+19.1%
Price Before
$14.50
Price After
$14.44
Q1 FY2024+0.80%
Report Date
Mar 19, 2024
EPS Beat/Miss
-8.0%
Price Before
$40.01
Price After
$40.33
Avg Beat Reaction+1.03%
Avg Miss Reaction+0.80%
Beat Rate7 / 8 quarters
Largest Move-8.68% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TRML ends December
Tourmaline Bio, Inc. (TRML) most recently reported earnings on November 6, 2025 for Q4 FY2025, posting EPS of $-0.78 — beating the analyst consensus of $-0.96 by +18.8%. TRML has beaten EPS estimates for 7 consecutive quarters. The next TRML earnings date is expected around September 1, 2026.
Each quarter, investors track TRML earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TRML revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TRML's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TRML earnings · 5 questionsTourmaline Bio, Inc.'s next earnings report is expected around September 1, 2026. TRML typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TRML historically reports after market close (AMC).
TRML earnings datewhen is TRML earningsTRML next earnings datewhen does TRML report earningsTRML earnings calendar
▸ Source: FMP · Tourmaline Bio, Inc. SEC filings · US GAAP · Tourmaline Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026